Purpose of the development: New compounds has developed for the early detection and treatment of cancer diseases of bone tissue and mammary gland and localization of metastases.

Recommended application field: The compounds have promise in new low-toxicity drugs with targeted and selective action for the treatment of cancer diseases of bone tissues and mammary gland and localization of metastases by chemo- and radiotherapy.

Advantages over analogues: At the present time, in the medical practice there are no drugs for the direct treatment of cancer diseases of bone tissues, not to mention targeted drug delivery and selective action only on cancer cells. The effect of targeted antineoplastic action of our compounds is due to the combination, in the substances, of chemically bound metal ion with antitumor properties with molecule, which is biocompatible with the living organism, primarily with bone tissues, and delivers the substance to cancer-affected bone tissues. The effect of selective action of the substance will be achieved by making one more molecule, which is actively absorbed by cancer cells, a part of the compound. The synthesis methods developed do not require expensive equipment. Our compounds are two or three times cheaper than cisplatin. The basis of the early spectroscopic detection of cancer diseases is structural differences between the constituents of sound and cancer-affected tissues, which manifest themselve in spectra. Independent morphological and spectroscopic investigations of the same tissues of healthy and ill patients gave a 100% convergence of results. The advantages of the method developed are the rapidity and validity of the detection of the absence or existence of cancer disease before its clinical presentations without extensive operative intervention. Tissue can be sampled by laparoscopy in the clinic using a device that is already produced or a new cheaper device with narrow spectral range.

The development stage readiness: tested in laboratory condition

Description of the development:
()
The drugs used for the treatment of cancer diseases by chemotherapy and radiotherapy have a number of considerable disadvantages: 1. Drug delivery to the focus of cancer disease is not targeted: the drug spreads throughout the organism; reduced action efficiency; necessity of the refresher course of treatment, which leads to an increase in cost. 2. The nonselective action of drug results in the affection of both cancer cells and healthy cells. 3. High overall and specific toxicity of drugs, which results in the affection of kidneys, liver, etc, when platinum compounds are used. 4. For most drugs, the habituation of the organism to them with retention of toxicity was noted, which requires increasing the introduced dose or replacement. We have developed, physicochemically characterized and tested in vivo and in vitro substances, which are comparable with cisplatin [Pt(NH3)2Cl2] now in use in antineoplastic action. However, their total toxicity (LD50) is 2-10 times lower than that of cisplatin. Their use does not cause the affection of kidneys, liver, etc, which is typical of cisplatin. The substances accumulate right in bone tissues, mainly in the backbone. Even the intraperitoneal introduction of solutions of compounds results in the disappearance of metastases in lungs. We are planning to obtain substances with both targeted and selective action on cancer cells. The absence of the effect of habituation of the organism to them is supposed. The fundamentals of the synthesis of substances for the targeted delivery of radionuclides to bone tissues for radiotherapy and substances with combined radio- and chemotherapeutic action have been worked out. The treatment efficiency is determined by the diagnosis of disease. The early detection of the signs of disease increases the possibility of ultimate recovery or prolongation of the active life of patient. A practically universal spectroscopic method of diagnosis at the earliest stages of disease, which have no clinical presentations yet, has been developed. The difference criteria of the spectrum of sound and cancer-affected human tissues have been established. The method allows one to distinguish with 100% guarantee between sound tissues, tissues with nonmalignant lesions and canceraffected tissues.

Information about newness of the development:
there are Ukrainian patents -- 2 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua